The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Benign Prostatic Hyperplasia (BPH) Treatment Market Research Report 2024
Synopsis
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
The global Benign Prostatic Hyperplasia (BPH) Treatment market was valued at US$ 3385 million in 2023 and is anticipated to reach US$ 3817.7 million by 2030, witnessing a CAGR of 2.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Treatment.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Viatris
Abbott
Allergan
TEVA
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
The global Benign Prostatic Hyperplasia (BPH) Treatment market was valued at US$ 3385 million in 2023 and is anticipated to reach US$ 3817.7 million by 2030, witnessing a CAGR of 2.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Treatment.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Viatris
Abbott
Allergan
TEVA
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Perspective (2019-2030)
2.2 Benign Prostatic Hyperplasia (BPH) Treatment Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Dynamics
2.3.1 Benign Prostatic Hyperplasia (BPH) Treatment Industry Trends
2.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
2.3.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges
2.3.4 Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia (BPH) Treatment Revenue
3.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2023
3.5 Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2025-2030)
5 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)
6.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)
6.4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)
7.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)
9.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)
9.4 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.1.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.3.5 Astellas Pharma Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.4.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Viatris
11.5.1 Viatris Company Detail
11.5.2 Viatris Business Overview
11.5.3 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.5.4 Viatris Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.5.5 Viatris Recent Development
11.6 Abbott
11.6.1 Abbott Company Detail
11.6.2 Abbott Business Overview
11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.6.4 Abbott Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.6.5 Abbott Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.7.5 Allergan Recent Development
11.8 TEVA
11.8.1 TEVA Company Detail
11.8.2 TEVA Business Overview
11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.8.4 TEVA Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.8.5 TEVA Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.9.4 Novartis Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Benign Prostatic Hyperplasia (BPH) Treatment Introduction
11.10.4 Merck Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
11.10.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha-Blocker
Table 3. Key Players of Phosphodiesterase Type-5 Inhibitors
Table 4. Key Players of Others
Table 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2019-2024)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2025-2030)
Table 11. Benign Prostatic Hyperplasia (BPH) Treatment Market Trends
Table 12. Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
Table 13. Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges
Table 14. Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints
Table 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players (2019-2024)
Table 17. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2023)
Table 18. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service
Table 22. Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Eli Lilly Company Detail
Table 48. Eli Lilly Business Overview
Table 49. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 50. Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 51. Eli Lilly Recent Development
Table 52. GlaxoSmithKline Company Detail
Table 53. GlaxoSmithKline Business Overview
Table 54. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 55. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 56. GlaxoSmithKline Recent Development
Table 57. Astellas Pharma Company Detail
Table 58. Astellas Pharma Business Overview
Table 59. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 60. Astellas Pharma Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 61. Astellas Pharma Recent Development
Table 62. Sanofi Company Detail
Table 63. Sanofi Business Overview
Table 64. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 65. Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 66. Sanofi Recent Development
Table 67. Viatris Company Detail
Table 68. Viatris Business Overview
Table 69. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 70. Viatris Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 71. Viatris Recent Development
Table 72. Abbott Company Detail
Table 73. Abbott Business Overview
Table 74. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 75. Abbott Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 76. Abbott Recent Development
Table 77. Allergan Company Detail
Table 78. Allergan Business Overview
Table 79. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 80. Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 81. Allergan Recent Development
Table 82. TEVA Company Detail
Table 83. TEVA Business Overview
Table 84. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 85. TEVA Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 86. TEVA Recent Development
Table 87. Novartis Company Detail
Table 88. Novartis Business Overview
Table 89. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 90. Novartis Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 91. Novartis Recent Development
Table 92. Merck Company Detail
Table 93. Merck Business Overview
Table 94. Merck Benign Prostatic Hyperplasia (BPH) Treatment Product
Table 95. Merck Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024) & (US$ Million)
Table 96. Merck Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type: 2023 VS 2030
Figure 3. Alpha-Blocker Features
Figure 4. Phosphodiesterase Type-5 Inhibitors Features
Figure 5. Others Features
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players in 2023
Figure 16. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2023
Figure 18. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)
Figure 20. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)
Figure 24. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2019-2030)
Figure 32. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)
Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2019-2030)
Figure 44. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Eli Lilly Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 47. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 48. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 49. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 50. Viatris Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 51. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 52. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 53. TEVA Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 54. Novartis Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 55. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
